Metacrine Inc. (MTCR) News
Filter MTCR News Items
MTCR News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Latest MTCR News From Around the Web
Below are the latest news stories about METACRINE INC that investors may wish to consider to help them evaluate MTCR as an investment opportunity.
Metacrine and Equillium Mutually Agree to Terminate Definitive Merger AgreementLA JOLLA, Calif., Dec. 23, 2022 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR) and Equillium, Inc. today announced the mutual termination of their previously announced definitive merger agreement. Metacrine is continuing to evaluate all strategic opportunities. Additional information regarding the termination of the definitive merger agreement is provided set forth in a Current Report on Form 8-K filed by Metacrine with the U.S. Securities and Exchange Commission today and is available at www |
Metacrine Reports Third-Quarter 2022 ResultsSAN DIEGO, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company developing differentiated therapies for patients with gastrointestinal diseases, today reported its third-quarter 2022 financial results. “We made great progress during the quarter in advancing our proposed merger with Equillium,” said Preston Klassen, M.D., MHS, president and chief executive officer of Metacrine. “We believe that Equillium has demonstrated compelling clinical d |
Why Is Equillium (EQ) Stock Soaring 20% Today?Biotech firm Equillium is on the move as it released positive data for a lupus therapeutic, though EQ stock has a tough road ahead. |
Equillium Buys Inflammatory Bowel Disease Player In All-Stock DealEquillium Inc (NASDAQ: EQ) has agreed to acquire Metacrine Inc (NASDAQ: MTCR) in an all-stock transaction. The transaction is anticipated to add $33 million in cash to Equillium's balance sheet at closing, which is expected to extend the company's cash runway into 2024. Earlier this year, Metacrine axed 50% of its workforce. Through the acquisition, Equillium adds Metacrine's farnesoid X receptor platform, including lead molecule MET642 for inflammatory bowel diseases. Equillium will be seeking |
Equillium to Acquire Metacrine in All-Stock TransactionLA JOLLA, Calif., September 06, 2022--Equillium, Inc. (Nasdaq: EQ) and Metacrine Inc. (Nasdaq: MTCR), today announced that the two companies have entered into a definitive merger agreement pursuant to which Equillium will acquire Metacrine in an all-stock transaction. The transaction is anticipated to add $33 million in cash to Equillium’s balance sheet at closing, which is expected to extend the company’s cash runway into 2024. The transaction has been approved by the boards of directors of bot |
H.C. Wainwright Remains a Hold on Metacrine (MTCR)E ratio of -0.32. |
Metacrine Reports Second-Quarter 2022 ResultsSAN DIEGO, Aug. 09, 2022 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with gastrointestinal diseases, today reported its second-quarter 2022 financial results. “We have made meaningful progress during the quarter in evaluating strategic alternatives designed to maximize stockholder value,” said Preston Klassen, M.D., MHS, president and chief executive officer of Metacrine. Potential strategic altern |
Metacrine Reports First-Quarter 2022 ResultsSAN DIEGO, May 12, 2022 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with gastrointestinal diseases, today reported its first-quarter 2022 financial results and provided a business update. Metacrine announced today that it has engaged a strategic financial advisor and initiated a review of strategic alternatives with the goal of maximizing shareholder value. Potential strategic alternatives to be ex |
Metacrine Reports Fourth-Quarter 2021 ResultsSAN DIEGO, March 30, 2022 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with gastrointestinal diseases, today reported its fourth-quarter 2021 financial results. “We continue to devote all of our development effort to bringing expanded therapeutic options to people living with ulcerative colitis (UC),” said Preston Klassen, M.D., MHS, CEO, Metacrine. “We have generated preclinical data that supports |
Metacrine Announces Executive Leadership ChangesSAN DIEGO, Feb. 24, 2022 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with gastrointestinal diseases, today announced that Ms. Trisha Millican has resigned her position as chief financial officer. Ms. Millican will remain with the Company until March 31, 2022 to ensure a smooth transition. In addition, Mr. Michael York, currently senior vice president, business development and commercial strategy, h |